p = 0.09), suggesting a lack of substantial difference between the efficacy of Semaglutide and Liraglutide (Figure 7)
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Working in concert with GLP-1, GIP activation further augments insulin release and contributes to feelings of satiety
Zepbound (Tirzepatide Injection): This injectable is renowned for its effectiveness, activating both GLP-1 and GIP receptors
Weekly self-administered subcutaneous injection using a small needle (similar to insulin)
If nausea sticks around, try plain foods like crackers, toast, rice, or bananas
This approval represents a significant advancement toward personalized lipid management by providing a highly effective, needle free alternative that may enhance long term adherence and ultimately reduce the burden of atherosclerotic cardiovascular disease